Tscan Therapeutics is trading at $0.57, down -13.72%, with no clear company-specific catalyst identified for September 2, 2026.
- No fresh company-specific announcement, filing, or analyst action was identified for September 2, 2026.
- The latest major update remains the August 12, 2026, second-quarter report; an Amgen collaboration termination was disclosed in an August 18 filing.
- Broader markets are only modestly weaker, so macro sentiment alone does not clearly explain the decline.